New update expands the library of virtual populations and enhances connections between software platforms
Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference
Chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
Management will be presenting at Baird’s 2022 Global Healthcare Conference
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
ILDsym will enable new software and services revenue by aiding development of therapies for the treatment of patients with ILD as a complication of systemic sclerosis
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
Extensive data sharing with large pharmaceutical partner will expand property prediction space and improve model performance
Simulations Plus Presented New Scientific Developments at PAGE 2022
Several posters and oral presentations involved the use of MonolixSuite®
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
Tenured employees support St. Jude in finding cures and saving children
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%;
Diluted Earnings Per Share (EPS) growth of 11%;
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
Record-setting attendance for the global pharmacometrics community
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
Simulations Plus' Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy.
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
DILIsym application contributes to approval of new drugs for migraine treatment
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
FDA Renewal Ensures Access for DILIsym Evaluation of Drug Candidate Submissions
Simulations Plus Successfully Delivers FDA-Funded Project
Collaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
Funded partnership with large pharmaceutical company will enhance mechanistic dissolution models for injectable formulations
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40%
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
SLP will partner with the University of Pittsburgh and its Liver-on-a-Chip platform
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development